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Abstract
Background—Our purpose was to identify physicians’ individual characteristics, attitudes, and
organizational contextual factors associated with higher enrollment of patients in cancer clinical
trials among physician participants in the National Cancer Institute’s Community Clinical
Oncology Program (CCOP). We hypothesized that physicians’ individual characteristics, such as
age, medical specialty, tenure, CCOP organizational factors (i.e., policies and procedures to
encourage enrollment), and attitudes towards participating in CCOP would directly determine
enrollment. We also hypothesized that physicians’ characteristics and CCOP organizational
factors would influence physicians’ attitudes towards participating in CCOP, which in turn would
predict enrollment.
Methods—We evaluated enrollment in National Cancer Institute sponsored cancer clinical trials
in 2011 among 481 physician participants using structural equation modeling. The data sources
include CCOP Annual Progress Reports, two surveys of CCOP administrators and physician
participants, and the American Medical Association Masterfile.
Results—Physicians with more positive attitudes towards participating in CCOP enrolled more
patients than physicians with less positive attitudes. In addition, physicians who practiced in
CCOPs that had more supportive policies and practices in place to encourage enrollment (i.e.,
offered trainings, provided support to screen and enroll patients, gave incentives to enroll patients,
instituted minimum accrual expectations) also significantly enrolled more patients. Physician
status as CCOP Principal Investigator had a positive direct effect on enrollment, while physician
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age and non-oncology medical specialty had negative direct effects on enrollment. Neither
physicians’ characteristics nor CCOP organizational factors indirectly influenced enrollment
through an effect on physician attitudes.
Conclusions—We examined whether individual physicians’ characteristics and attitudes, as
well as CCOP organizational factors, influenced patient enrollment in cancer clinical trials among
CCOP physicians. Physician attitudes and CCOP organizational factors had positive direct effects,
but not indirect effects, on physician enrollment of patients. Our results could be used to develop
physician-directed strategies aimed at increasing involvement in clinical research. For example,
administrators may want to ensure physicians have access to support staff to help screen and enroll
patients or institute minimum accrual expectations. Our results also highlight the importance of
recruiting physicians for volunteer clinical research programs whose attitudes and values align
with programmatic goals. Given that physician involvement is a key determinant of patient
enrollment in clinical trials, these interventions could expand the overall number of patients
involved in cancer research. These strategies will be increasingly important as the CCOP network
continues to evolve.
Keywords
Cancer; Clinical trial enrollment; Community Clinical Oncology Program; National Cancer
Institute Oncology Research Program; Organizational Design Features; Structural Equation
Modeling
Background
Cancer clinical trials are instrumental for developing innovative cancer treatments and
expanding current diagnostic, control, and prevention techniques [1,2]. Despite the potential
for positive health outcomes, only 3–5% of U.S adults with cancer participate in cancer
clinical trials [3]. To increase patient participation in trials, the Community Clinical
Oncology Program (CCOP), a cancer focused provider-based research network administered
by the National Cancer Institute, engages community physicians in clinical research to
enhance the translation of research results into practice [4]. Since its inception in 1983, the
CCOP network has generated over 50% of the enrollment in National Cancer Institute
sponsored cancer prevention and control trials and 30% of the enrollment in National Cancer
Institute sponsored cancer treatment trials [5].
Although the CCOP network has successfully increased overall cancer clinical trial
enrollment, individual physicians vary in their enrollment of patients in clinical trials. Many
participating physicians enroll no patients in a given year, while others enroll dozens. In
2011, approximately 40% of CCOP physicians enrolled no patients (mean: 3; range: 0–88).
Variation in physician enrollment has occurred since the program’s inception, yet the
reasons have not been systematically investigated. Research to date has focused on
identifying the organizational and environmental contextual factors that drive clinical trial
patient enrollment at the CCOP level [6– 9]. No research has examined physician and
organizational contextual factors associated with individual physicians’ success in enrolling
patients. These findings are critical to determine the context within which we can increase
enrollment of cancer patients in National Cancer Institute sponsored clinical trials and, in
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turn, the pace at which we identify and disseminate innovative therapies. Understanding
physician factors that drive patient enrollment will be critical in the organizational design of
the new National Cancer Institute Community Oncology Research Program, for example, by
setting minimum expectations for enrollment, recognizing high enrolling physicians, or
providing physicians with support [10]. Findings can also inform physician recruitment
efforts for National Cancer Institute Community Oncology Research Program.
This study seeks to identify the specific CCOP-affiliated physicians’ characteristics and
CCOP organizational contextual factors associated with higher enrollment of patients in
National Cancer Institute sponsored cancer clinical trials. The hypothesis is that
organizational contextual factors, such as trainings, support to enroll patients, expectations
for enrollment, physicians’ attitudes towards participating in clinical trials, and individual
characteristics, such as age, tenure, medical specialty will directly and indirectly affect their
enrollment of patients in trials.
Methods
Theoretical Framework
The conceptual model is adapted from the Multilevel Framework of Organizational and
Individual Innovation Adoption [11]. Although this framework was developed in the
marketing and management literature, it has become a common approach to address
innovation implementation in health and human services research as well. For example, the
framework has been integrated as part of the Consolidated Framework for Implementation
Research, which seeks to advance the implementation of health services research findings
into practice [12]. An attractive feature of this framework is that it includes factors at both
the organizational and individual levels to predict innovation adoption [11]. In this study we
focused on adoption among individual physicians.
The original model as developed by Frambach and applied to this setting is presented in
Figure 1. The model postulates that social usage of the innovation, such as social norms,
expectations, peer usage, and personal disposition towards innovativeness (i.e., tendency to
accept an innovation regardless of others) directly determines individual innovation
acceptance. Innovation acceptance in this study is participation in clinical trials, defined as
the number of patients CCOP physicians enrolled in National Cancer Institute sponsored
cancer clinical trials in 2011. The model also suggests that social usage and personal
disposition towards innovativeness determines individuals’ attitudes towards using the
innovation, which in turn determines innovation acceptance. Also included in the model are
organizational facilitators (e.g., training, support, incentives) and individual characteristics
(e.g., demographics, experience) that may also indirectly influence innovation acceptance
through individuals’ attitudes and personal disposition towards innovativeness respectively.
The model we tested adheres to the basic structure of the framework proposed by Frambach
[11]; however, based on data availability, theory, and knowledge of CCOP network
operation, we made three changes to the original model before analyzing any data. The
tested model is presented in Figure 2. First, we combined social usage and organizational
facilitators into one construct, organizational context. We did this for two reasons: (1) it
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makes theoretical sense as all the data used for this construct is at the CCOP level and (2)
we only had two observed variables, peer enrollment and expectations, to construct social
usage, but the statistical modeling approach required we use at least three observed variables
[13]. The second change is that we did not include personal disposition towards
innovativeness in our model because we lacked data on this construct. Lastly, we included
individual values as a component of attitudes rather than an individual characteristic. We
decided to do this because our survey instrument included values, along with general affect,
beliefs towards the ease of participation, and complexity of clinical trials as components of
attitudes towards innovation adoption. Therefore it made theoretical sense to include values
as a component of attitudes versus an individual characteristic.
Study Setting and Sample
The CCOP network is a joint venture between the National Cancer Institute Division of
Cancer Prevention, which provides overall direction and funding for community hospitals
and physicians to participate in clinical trials, clinical cooperative groups, and community-
based physicians and hospitals [14]. The CCOP research bases design and conduct clinical
trials, and individual community-based physicians and hospitals assist with patient
enrollment, data collection, and dissemination of study findings [5,14]. When the data were
collected in 2011, 47 CCOPs operated in 28 states with approximately 3,500 participating
community physicians.
The sample is comprised of physicians who responded to the 2011 CCOP Physician Survey.
We used a stratified (by CCOP) random sample of 817 physicians across all 47 CCOPs. The
final sample included 485 physicians (59.4% of physicians surveyed). The only significant
(p<0.05) differences between survey responders and non-responders were that responders
enrolled more patients per year (4.7 versus 3.4), were more likely to be a surgeon (10%
versus 5%), and were less likely to be a non-specialized general oncologist (11% versus
24%). There were no significant differences between respondents and non-respondents
regarding gender, race, age, practice type, training location, and tenure. This study was
determined to be exempt from review by the Institutional Review Board at the University of
North Carolina at Chapel Hill.
Study Design and Data Sources
The data for this cross-sectional study were obtained from four sources. The 2011 CCOP
Progress Reports provided data on physicians’ enrollment activity from June 1, 2011 to
February 29, 2012. The 2011 CCOP Administrator Survey and the 2011 CCOP Physician
Survey were both administered as part of a larger National Cancer Institute funded-study
(5R01CA124402). The Physician Survey supplied data on CCOP physicians’ attitudes
towards participation in clinical trials. Responses were collected between October 2011 and
January 2012. The Administrator Survey provided information on the CCOP organizational
contextual factors. The majority of responses were collected at the annual CCOP meeting in
September 2011. Any remaining surveys were completed in October 2011. We achieved a
100% response rate from CCOP Administrators. Lastly, the 2012 American Medical
Association Physician Masterfile provided data on CCOP physicians’ individual
characteristics.
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Table 1 provides details on our measures. The outcome was the number of patients CCOP-
affiliated physicians enrolled in National Cancer Institute sponsored cancer clinical trials in
2011. Physician attitudes, a predictor construct, was composed of questions assessing
beliefs related to the complexity of trials, whether trials excluded too many patients, affect
towards whether trials explored important issues, and physicians’ values related to
participating in clinical trials. Organizational contextual factors, also a predictor construct,
included educational trainings offered, support provided by the CCOP to physicians to help
screen and enroll patients, incentives provided to physicians, peer usage (i.e., the average
number of patients enrolled in National Cancer Institute sponsored clinical trials for
physicians within a specific CCOP), and CCOP expectations for enrollment.
Physicians’ individual characteristics included age, practice type, tenure, physician training
location, medical specialty, and whether or not the physician is the CCOP Principal
Investigator.
Statistical Analysis
Structural Equation Modeling with maximum likelihood estimation was used to
simultaneously test the effects of the CCOP organizational contextual factors and physician
attitudes on enrollment. Structural Equation Modeling is composed of multivariate
regression models and can be used to estimate proposed causal relationships [15–18]. We
used confirmatory Structural Equation Modeling to test the hypothesized pathways among
factors represented in Figure 2 by comparing how well this proposed structure fits the
observed data. We elected to use Structural Equation Modeling because it allowed us to test
for constructs that are not directly assessed, but are instead composed of observed indicators
representing the constructs of interest (e.g., CCOP organizational contextual factors,
physician attitudes). We elected to use clustered robust standard errors to account for
clustering of physicians within 47 CCOPs. We then evaluated model fit using the
Comparative Fit Index and the Tucker-Lewis Index. Comparative Fit Index and the Tucker-
Lewis Index values range from 0 to 1, with values ≥ 0.90 representing adequate fit [15]. We
also examined the root mean square error of approximation, and the associated confidence
interval and p-value. Root mean square error of approximation values < 0.05 and an upper
bound of the confidence interval < 0.1 are considered acceptable [15]. Next, we examined
the standardized root mean squared residuals, standardized root mean squared residuals with
values < 0.08 considered acceptable fit [15]. We also evaluated our model by testing the
significance of all standardized estimates, including the direct and indirect effects of
variables on the outcome.
Based on these fit statistics for the original model in Figure 2, we elected to re-specify the
model to improve its fit. Structural Equation Modeling is an iterative process in which
model fit is improved by using theory and modifications indices either to add additional
pathways between variables or to allow items to co-vary [15–18]. Modification indices are
the minimum that the chi-square statistic is expected to decrease if the corresponding
parameter is no longer assumed to be fixed at zero [15]. When revising the model, we tested
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whether model fit improved by comparing the baseline model with the new model using the
Lagrange multiplier test and fit statistics.
Once we achieved a well-fitting model, we tested the significance of all standardized
estimates, including direct and indirect effects. Standardized parameter estimates are
transformations of unstandardized estimates that remove scaling and can be used for
informal comparisons of parameters throughout the model [15]. Direct effects are equal to
the regression coefficients (i.e., β) while indirect effects are the product of the two
regression coefficients. For example, if X predicts Y and Y predicts Z, then the indirect
effect of X on Z equals the product of the two regression coefficients (X on Y and Y on Z).
Lastly, to ensure the validity of our Structural Equation Modeling results, we checked our
results using negative binomial regression analysis with clustered robust standard errors.
Analyses were performed using Mplus 7.
Results
Study Population
The final sample included 481 physicians with complete information. Table 2 provides
descriptive statistics for the entire sample. Notably, 74% were male, 75% were White non-
Hispanic, and their mean age was 53 years; they have been in practice a mean of 26 years.
The vast majority practiced in group practices and trained in the United States; 72% were
oncology-based specialists, 10% were surgeons, and 18% reported another medical specialty
(e.g., gynecology, pediatrics, internal medicine). Physicians enrolled a mean of 5 patients in
2011 (range: 0–62); approximately 40% of physicians enrolled no patients in the 9-month
reporting period.
Structural Equation Modeling Analysis
The fit statistics and modification indices for the fixed parameters of the original model
tested in Figure 2 suggested that we re-specify the model to improve fit (Comparative Fit
Index = 0.648; Tucker-Lewis Index = 0.560; Root mean square error of approximation =
0.067; Standardized root mean squared residuals = 0.061). Therefore, we added seven post-
hoc modifications that were theoretically justified and improved model fit. Figure 3 presents
the final model with all post hoc modifications and standardized estimates. For these
modifications, we allowed the error terms of the following measures to co-vary higher than
with other variables. For example, the percentage of doctors supported in screening and
enrolling patients, likely share common variation that is not explained by any of the
proposed relationships in the model.
1 Peer-usage with the outcome: Peer-usage is based on the individual physicians’
enrollment within a specific CCOP. We co-varied the error terms as they likely
share common variation that is not explained by relationships in the model.
2 The percentage of doctors supported in screening and enrolling patients: The
same support staff generally preform both functions within a CCOP.
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3 Trainings offered with the percentage doctors who are supported in screening
and enrolling patients: The number of trainings offered relates to the number of
support staff available.
4 Incentives with expectations for enrollment: CCOPs that provide incentives may
also be more likely to have expectations for enrollment.
5 Affect with values: Providers who believe that trials explore important issue are
also likely to value participating.
6 Belief that trials are too complex with belief that trials exclude too many
patients: These relate to an overall negative view of CCOP and may discourage
participation.
7 Affect with whether physicians believe trials exclude too many patients:
Providers who report that trials are important are less likely to think they
exclude too many patients.
With the addition of each error co-variance, we tested the baseline model against the new
model for improved model fit. Overall, we achieved a final well-fitting model (Comparative
Fit Index = 0.936; Tucker-Lewis Index = 0.914; Root mean square error of approximation =
0.030; Standardized root mean squared residuals = 0.046) (Figure 3).
Table 3 provides standardized indirect, direct, and total effects for all of the variables and
constructs included in the model. In general, standardized effects of less than 0.10 constitute
a small effect; values greater than 0.30 indicate a medium effect; and values greater than
0.50 indicate a large effect [18]. Overall the effect sizes were fairly small for the latent
constructs of organizational context and individual attitudes, which had significant positive
direct effects on the outcome. For example, the direct effect of organizational context on
enrollment was β=0.19 (p=0.02) and for physician attitudes it was β=0.13 (p=0.04). In
addition, physician’s CCOP Principal Investigator status, age, and non-oncologist specialty
also had significant direct effects on enrollment. The most significant positive direct effect
was whether the physician was the Principal Investigator (β=0.35; p<0.00). Physician age
(β= −0.27; p=0.02) and non-oncology specialty (β= −0.14; p=0.03) had significant negative
direct effects on enrollment.
There was no evidence, however, that CCOP organizational context or any of the physician
individual characteristics significantly influenced accrual through their effects on physician
attitudes. Finally, training location, practice location, and physicians who are surgeons,
hematologists, and radiological oncologists (compared to non-specialized medical
oncologists) did not directly affect enrollment. Overall our model explained 21% of the
variance in patient enrollment. The robustness check of our Structural Equation Modeling
results using negative binomial regression analysis with clustered robust standard errors
confirmed our main findings that both organizational context and attitudes were significantly
associated with patient enrollment, along with physician status as the CCOP Principal
Investigator and medical specialty.
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We hypothesized that organizational contextual factors, physicians’ attitudes and individual
characteristics would have both direct as well as indirect effects operating through attitudes
on enrollment of patients in National Cancer Institute sponsored cancer clinical trials. This
hypothesis was partially supported as organizational context and physician attitudes had
positive significant direct effects on enrollment; however, there were no indirect effects on
enrollment operating through attitudes.
Consistent with the literature, we found that physicians’ attitudes towards participating in
CCOP directly impacted enrollment [19,20]. This was likely because physicians who viewed
participation as more useful and easy, had individual values aligned with CCOP goals, and
had more positive feelings were more active in enrolling patients in trials. This finding
highlights the importance of recruiting physicians for volunteer research programs who
value participating in clinical trials, find participating in trials important, and feel they are
able to do so. Recruiting physicians whose attitudes align with the program’s goals is
especially important for community sites interested in participating in the new National
Cancer Institute Community Oncology Research Program. Interestingly, organizational
context did not predict physicians’ attitudes. Changes in organizational context may
influence overall enrollment of patients as a supportive environment assists with accrual
efforts, but these contextual factors do not appear to impact the attitudes of physicians. This
finding further supports recruiting physicians with positive attitudes towards participating in
clinical research.
In addition, as hypothesized, CCOP organizational contextual factors made a difference.
Specifically, organizations that provided support for physicians to consent and enroll
patients, offered incentives for enrollment, and mandated expectations for enrollment also
increased physician enrollment, perhaps due to a strong sense of organizational commitment
and social norms. Program administrators of CCOPs or other voluntary research programs
might consider providing support for physicians’ research activities, such as staff to help
consent and enroll patients, incentives for enrollment goals (e.g., small tokens of
appreciation, public acknowledgment), and trainings to learn about latest developments in
research. Such strategies may not directly change physician attitudes, but may provide a
supportive organizational context to encourage active physician participation in recruiting
patients.
We were surprised that organizational context did not have an indirect effect on enrollment
by influencing physicians’ attitudes towards clinical trials. Perhaps physicians’ attitudes
were not a significant mediator of organizational context because physicians elect to
participate in CCOP. Although implementation of some innovations in healthcare may be
mandated, clinical trial participation, however, is not required. It may be that, specific
organizational contextual factors do not influence attitudes among physicians who have
already agreed to participate and recruit patients to clinical trials. Organizational context
may shape attitudes towards participation in other types of settings where participation or
implementation of a specific innovation is mandatory and attitudes would likely be more
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fluid. Therefore, organizational context would have more of an opportunity to determine
attitudes towards participation.
In addition, three physician characteristics also significantly effected enrollment. Being a
CCOP Principal Investigator was the strongest predictor. Principal Investigators are more
likely than non- Principal Investigators to be committed to the CCOP and feel obligated to
set a “good example” for their colleagues. Principal Investigators may also be more familiar
with available trial protocols and receive greater assistance from support staff to consent and
enroll patients. A strong negative predictor of enrollment was whether the physician was a
non-oncology specialist. This finding was consistent with the literature [19,21] One reason
may be that non-oncologists feel less comfortable and/or familiar with cancer protocols than
oncologists. In addition, physician age also had significant negative direct effects on
enrollment.
We were surprised that practice location, foreign medical training, and medical specialty
(with the exception of non-oncology) did not impact enrollment. Although none of the
previous studies exclusively examined enrollment among CCOP physicians, past studies
found that practice type (i.e., office-based practice compared to hospital based practice) and
medical specialty (i.e., medical oncologists compared to radiation oncologists) increased
physician enrollment of patients while foreign-trained oncologists enrolled fewer patients. In
our study, practicing at a hospital or as a solo physician (compared to a group practice) may
not have had a significant effect because it was difficult to discern a physician’s main
practice location [19,21]. In addition, many CCOP physicians travel between different
offices, which may make their primary location less relevant. We suspect that foreign
medical training did not impact enrollment because we could not determine how long
physicians had been practicing in the U.S., which is likely a more relevant predictor of
enrollment than training location. In addition, medical specialty may not be as influential on
enrollment as there are an abundance of types of cancer clinical trials, including protocols
for surgery and radiological interventions. Therefore all cancer-related specialties are
comfortable and willing to enroll patients in cancer trials.
Limitations
There are several limitations of our study. First, we only included physicians who participate
in CCOPs. These physicians have already agreed at least on some level to participate in
CCOP. Therefore our findings suggest the organizational and individual factors that are
most relevant to encourage active participation in CCOP. It is important to note, however,
that many organizational strategies (e.g., recognition of high achievers, expectations for
enrollment) could be implemented by diverse organizations to increase physician
participation in clinical research. Second, we are unable to account for variation in the
number of potentially eligible patients physicians see. Therefore, we were unable to
distinguish physicians failing to offer a cancer clinical trial from patients’ refusal to enroll.
We also lacked the data to incorporate patient-level characteristics in the analyses. We
cannot account for variations in patients’ cancer stage, co-morbidities, age, or any other
factors that may determine eligibility. Ultimately patients are the final decision makers
regarding their participation in a cancer clinical trial. However, given that 75% of patients
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agree to enroll if offered [22], we do not believe this to be a significant limitation of this
study. Third, given that we were only able to explain 21% of the variance in enrollment, we
were also limited in the data that was available to examine individual physician enrollment.
Future studies may want to consider including additional factors, such as patient-level
characteristics in the model to increase the amount of variation explained. In addition, more
information on physician behaviors and personality traits (e.g., personal disposition to
innovativeness, goal-orientation) may also help to explain variance in enrollment in cancer
clinical trials.
We believe this study extends the literature in several important ways. First, it is the first
study to evaluate physician-level predictors of their success in enrolling patients in CCOP
cancer clinical trials. Second, it provides the basis of physician-directed strategies that may
effectively promote enrollment of patients in cancer clinical trials. By expanding the number
of patients involved in cancer clinical trials, we can accelerate the pace in which we identify
promising innovative therapies and novel interventions that can ultimately improve the
outcomes of cancer patients.
Conclusions
The findings from this study are important for program administrators looking to increase
volunteer physician participation in clinical research as well for new National Cancer
Institute Community Oncology Research Program sites. Our results suggest two strategies to
increase participation. The first is to ensure physicians attitudes and values align with the
programmatic goals. For example, recruiting physicians who value participating in clinical
trials, find participating in trials important, and feel they are able to do so is a key
determinant of a program’s success. Recruitment of physicians whose values align with
program goals is especially important given that CCOP organizational context did influence
attitudes towards participation. Second, program administrators should consider providing
support for physicians’ research activities, such as staff to help consent and enroll patients,
incentives for enrollment goals (e.g., small tokens of appreciation, public acknowledgment),
and trainings to learn about latest developments in research. Such strategies may not directly
change physician attitudes, but may provide a supportive organizational context to
encourage active physician participation in recruiting patients.
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Original Model of Individual Innovation Acceptance in Organizations as Applied to CCOP
Physician Enrollment of Patients in Cancer Clinical Trials
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Tested Model of Individual Innovation Acceptance in Organizations
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Standardized SEM Results for Final Model
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Table 1
Overview of Variables and Measures
Model Construct Variable Measure Measure Type Data Source
Outcome Variable
Innovation Acceptance Outcome: Enrollment of
Patients
No. of patients enrolled
in NCI-sponsored
cancer clinical trials in
2011
Continuous CCOP Progress Reports
Predictor Variables
Attitudes Affect NCI-sponsored trials
explore clinical issues
that are important in
my practice
Continuous:
1=Disagree to 5 =
Agree
CCOP-Affiliated Physician Survey




1=Disagree to 5 =
Agree
CCOP-Affiliated Physician Survey
Attitudes Beliefs: Trials Complex NCI-sponsored trials
are too complex to do
in my practice
Continuous:
1=Disagree to 5 =
Agree
CCOP-Affiliated Physician Survey




1=Disagree to 5 =
Agree
CCOP-Affiliated Physician Survey







Binary: 0 = N;
1=Y
CCOP Administrator Survey






Continuous CCOP Administrator Survey





Continuous CCOP Administrator Survey
Organizational Context Incentives CCOP provide some
form of recognition to
Type-A physicians with
high levels of accrual to
NCI-sponsored trials?
Binary: 0 = N;
1=Y
CCOP Administrator Survey
Organizational Context Peer Usage Average no. of patients
enrolled in NCI-
sponsored clinical trials
by physicians in CCOP
Continuous CCOP Progress Reports
Organizational Context Persuasion CCOP expect Type-A




Binary: 0 = N;
1=Y
CCOP Administrator Survey
Individual Characteristics Age The current year minus
the physicians’ year of
birth
Continuous AMA Provider Masterfile
Individual Characteristics Practice Type Indicator of present
primary employment
Categorical AMA Provider Masterfile
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Model Construct Variable Measure Measure Type Data Source
arrangement (e.g., solo,
group, hospital)
Individual Characteristics U.S Trained Indicator if physician
trained in the U.S.
Binary: 0 = N;
1=Y
AMA Provider Masterfile
Individual Characteristics PI Please indicate the PI
of the CCOP
Binary: 0 = N;
1=Y
CCOP Progress Reports






Categorical AMA Provider Masterfile
Individual Characteristics Tenure No. of years since
graduated medical
school
Continuous AMA Provider Masterfile
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Table 2
Descriptive Statistics: Physician Level Variables
CCOP Survey Respondents n=481
Mean or Proportion of Sample Range
Outcome
2011 Patient Enrollment 4.7* (8.1) 0, 62
Descriptive Variables
Gender
  Male 74%
  Female 26%
Race
  White 75%
  Asian 15%
  African-American 1%
  Other 9%
Variables included in Model Attitudes
Affect 4.6 (0.7) 2,5
Beliefs: Exclude Pts. 3.4 (1.2) 1,5
Beliefs: Complexity of Trials 2.4 (1.2) 1,5
Values 4.7 (0.6) 1,5
Personal Characteristics
Age 52.6 (9.8) 34,82
Practice Type
  Group Practice 78%
  Hospital-Based 12%
  Solo Practice 4%
  Other/None Listed 6%
Training Location
  U.S Trained 80%
  Non U.S Trained 20%
Tenure (Yrs. In Practice) 25.7 (10.1) 8, 57
Medical Specialty
  Hematology Oncology 40%
  Radiation Oncology 21%
  Other Specialty 18%
  Medical Oncology 11%*
  Surgery 10%*
Principal Investigator 9%
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Standard deviations in parentheses
*
Indicates significant difference between survey respondents and non-survey respondents
Other race includes American Indian, Native Hawaiian/Pacific Islander, More than one race, or unknown
Hematology oncology includes blood banking, hematology oncology, hematology
Radiation Oncology includes diagnostic radiology, nuclear medicine, radiation oncology, radiology, vascular and interventional radiology
Other specialist includes general practice, gynecological oncology, pediatrics, pediatric hematology, cardiovascular disease etc.
Surgery includes colon and rectal surgery, critical care sugary, general surgery, neurological surgery, surgical oncology, urological surgery etc.
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Table 3
Standardized Total, Direct, and Indirect Effects
Total Effect Direct Effect Indirect Effect
Outcome: Enrollment in NCI-Sponsored Cancer Clinical Trials in 2011
Physician Attitudes Construct 0.130* 0.130* N/A
Organizational Context Construct 0.205* 0.185* 0.020
Age −0.301* −0.271* −0.030
Hospital-Based^ −0.024 −0.040 0.016
Solo Practice^ 0.000 −0.004 0.004
Non U.S. Trained 0.004 −0.004 0.007
PI 0.360* 0.350* 0.010
Tenure 0.251* 0.214 0.037
Hematologist Oncology+ −0.127 −0.134 0.007
Radiation Oncology+ −0.132 −0.103 −0.029
Surgery+ −0.089 −0.076 −0.013
Other Specialty+ −0.146* −0.135* −0.011
Model Fit Statistics: CFI=0.936; TLI= 0.914; RMSEA=0.030; SRMR=0.046
Note: Total effects is the sum of direct and indirect effects
Note: Indirect effects are the product of the regression coefficients leading to the outcome. For example for organizational context, context predicts






Compared to Group Practice
+
Compared to General Non-Specialized Oncology
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